Humanwell Healthcare (600079) H1 2025 earnings summary

Executive summary

• Revenue for H1 2025 was ¥12.06 billion, down 6.20% year-over-year, mainly due to industry payment-side reforms and business structure optimization.

• Net profit attributable to shareholders reached ¥1.15 billion, up 3.92% year-over-year; adjusted net profit (excluding non-recurring items) was ¥1.13 billion, up 3.81%.

• The company maintained its leadership in core segments such as anesthetics, steroid hormones, and Uyghur medicines, with significant R&D and international expansion.

• Major subsidiaries contributed stable or growing revenues, with notable growth in neurology drugs and new product launches in key areas.

Financial highlights

• Operating income: ¥12.06 billion, down 6.20% year-over-year.

• Net profit attributable to shareholders: ¥1.15 billion, up 3.92% year-over-year.

• Operating cash flow: ¥858 million, up 1.48% year-over-year.

• Basic and diluted EPS: ¥0.71, up 4.41% year-over-year.

• Gross margin improved due to cost control and product mix optimization.

Outlook and guidance

• The company will continue to focus on core business areas, optimize asset structure, and enhance R&D and internationalization.

• Management expects ongoing industry reforms and market competition to drive further transformation and high-quality growth.